There are exciting research developments that promise to fundamentally impact the treatment of IgA nephropathy. This includes results of new clinical trials, as well as innovative trials of novel approaches to IgAN treatment. During this talk, the results of clinical trials of new supportive and immunosuppressive treatments will be reviewed; treatment challenges and unmet clinical needs will be highlighted. There will also be an overview of how new understanding of the pathophysiology of IgAN has broadened opportunities for trials of novel targeted therapies for this important global cause of kidney disease.
Learning Objectives:
Understand results and implications of new clinical trials in IgAN
Be able to compare trial results and populations.
Be familiar with novel targeted therapeutic approaches to treatment of IgAN under investigation.
Moderator: Marina Vivarelli (Rome, ERKNet WG lead for immune glomerulopathies)
Speaker: Vivekanand Jha (India) and Heather Reich (Canada)
Wednesday, 20th July 2020 at 4 pm (CET): Register here
